Evidence map›Paper›PMID 40471924›Full record

ArticlePloS one2025

Modeling the SARS-CoV-2 epidemic and the efficacy of different vaccines across different network structures.

Gregg Hartvigsen, Yannis Dimitroff

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gregg HartvigsenBiology Department, SUNY College at Geneseo, Geneseo, New York, United States of America.ORCID https://orcid.org/0000-0002-2277-7692
Yannis DimitroffBiology Department, SUNY College at Geneseo, Geneseo, New York, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed a network-based SEIRV model to test different vaccine efficacies on SARS-CoV-2 (Betacoronavirus pandemicum) dynamics in a naive population of 25,000 susceptible adults. Different vaccine efficacies, derived from data, were administered at different rates across a range of different Watts-Strogatz network structures. The model suggests that differences among vaccines were of minor importance compared to vaccination rates and network structure. Additionally, we tested the effect of strain differences in transmissibility (R0 values of 2.5 and 5.0) and found that this was the most important factor influencing the number of individuals ultimately infected. However, network structure was most important in affecting the maximum number of individuals that were infectious during the epidemic peak. The interaction of network structure, vaccination effort, and difference in strain transmissibility was highly significant for all epidemic metrics. The model suggests that differences in vaccine efficacy are not as important as vaccination rate in reducing epidemic sizes. Further, the importance of the evolution of viral transmission rates and our ability to develop effective vaccines to combat these strains will be of primary concern for our ability to control future disease epidemics.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacyAdultEpidemicsHumansPandemicsVaccinationCOVID-19 Vaccines

Identifiers

PMID40471924
PMCPMC12140218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.